Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX): No stopping the stock surge? – Stocks Register
Home  »  Business   »  Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX): No s...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX): No stopping the stock surge?

The trading price of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) closed higher on Monday, May 17, closing at $1.33, 3.76% higher than its previous close.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Traders who pay close attention to intraday price movement should know that it fluctuated between $1.3001 and $1.4200. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 1.59. In examining the 52-week price action we see that the stock hit a 52-week high of $3.5 and a 52-week low of $0.63. Over the past month, the stock has gained 20% in value.

Salarius Pharmaceuticals, Inc., whose market valuation is $56.65 Million at the time of this writing, is expected to release its quarterly earnings report Jul 14, 2021- Jul 19, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.05 per share this quarter, however they have predicted annual earnings per share of -$0.23 for 2021 and -$0.29 for 2022. It means analysts are expecting annual earnings per share growth of -0.54% this year and 0.26% next year.

On the technical side, indicators suggest SLRX has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 50% Buy.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned SLRX a recommendation rating is 2. Out of them, no one rate it a Hold, while 2 recommend Buy, whereas none assign an Outperform rating. None analyst(s) have tagged Salarius Pharmaceuticals, Inc. (SLRX) as Underperform, while not any of them advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that SLRX’s price is currently 12.1% off the SMA20 and 2.25% off the SMA50. The RSI metric on the 14-day chart is currently showing 57.25, and weekly volatility stands at 1169%. When measured over the past 30 days, the indicator reaches 9.27%. Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX)’s beta value is currently sitting at 1.59, while the Average True Range indicator is currently displaying 0.11. With analysts defining $3.8-$5 as the low and high price targets, we arrive at a consensus price target of $4.4 for the trailing 12-month period. The current price is about 175.36% off the estimated low and 262.32% off the forecast high, based on this estimate. Investors will be thrilled if SLRX’s share price rises to $4.4, which is the median consensus price. At that level, SLRX’s share price would be +218.84% above current price.

To see how Salarius Pharmaceuticals, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: SLRX stock’s performance was +3.76% in the latest trading, and +62.33% in the past year, while Zoetis Inc Cl A (ZTS) has traded -1.17% on the day and positioned +33.56% higher than it was a year ago. Another comparable company Takeda Pharmaceutical Co. Ltd (TAK) saw its stock close 0.47% higher in the most recent trading session but was down -7.48% in a year. Furthermore, Catalent Inc (CTLT) showed an increase of 3.76% on the day while its price kept rising at 62.33% over the past year. Salarius Pharmaceuticals, Inc. has a P/E ratio of 0, compared to Zoetis Inc Cl A’s 45.91 and Takeda Pharmaceutical Co. Ltd’s 32.7. Also in last trading session, the S&P 500 Index has soared -0.25%, while the Dow Jones Industrial also saw a negative seesion, down -0.16% on the day.


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



An evaluation of the daily trading volume of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) indicates that the 3-month average is 2.78 Million. However, this figure has increased over the past 10 days to an average of 567.3 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Currently, records show that 44.73 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 1.47% of outstanding shares, whereas institutions hold 14%. The stats also highlight that short interest as of April 14, 2021, stood at 1.37 Million shares, resulting in a short ratio of 1.61 at that time. From this, we can conclude that short interest is 3.07% of the company’s total outstanding shares. It is noteworthy that short shares in April were up slightly from the previous month’s figure, which was 1.11 Million. However, since the stock’s price has seen +51.65% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.

Leave a Comment

Your email address will not be published. Required fields are marked *

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.